Angiotensin II type 1 receptor antagonist downregulates nonmuscle myosin heavy chains in spontaneously hypertensive rat aorta.

The aim of this study was to clarify the differences between the angiotensin II type 1 (AT1) receptor antagonist and the angiotensin-converting enzyme (ACE) inhibitor on smooth muscle and nonmuscle myosin heavy chain isoforms in aortic smooth muscle cells of Wistar-Kyoto rats and spontaneously hypertensive rats. All 4 myosin heavy chain isoforms are heterogeneously expressed in the smooth muscle cells of the aortic tunica media in 20-week-old rats, and the contractile-type myosin heavy chains are highly expressed in smooth muscle cells of the aortic tunica media compared with the synthetic-type myosin heavy chains. Both the AT1 receptor antagonist and the ACE inhibitor had the same effects on hemodynamics, smooth muscle cell hypertrophy and proliferation, fibrosis, and vascular remodeling in spontaneously hypertensive rats. However, the AT1 receptor antagonist had a more potent effect on the downregulation of the synthetic-type myosin heavy chains than the ACE inhibitor in spontaneously hypertensive rat aortic tunica media. In contrast, these effects of the AT1 receptor antagonist and the ACE inhibitor on hemodynamics, morphology, fibrosis, and expression of myosin heavy chain isoforms in smooth muscle cells of the aortic tunica media were not observed in Wistar-Kyoto rats. Thus, within 6 weeks, the AT1 receptor antagonist might modulate the cellular composition of myosin heavy chain isoforms in smooth muscle cells more efficiently than the ACE inhibitor, without morphological changes in the spontaneously hypertensive rat aorta.

[1]  T. Ichiki,et al.  Angiotensin II receptors AT1 and AT2--new mechanisms of signaling and antagonistic effects of AT1 and AT2. , 1997, Japanese circulation journal.

[2]  P. Poitevin,et al.  Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[3]  C. Rosendorff.  The renin-angiotensin system and vascular hypertrophy. , 1996, Journal of the American College of Cardiology.

[4]  T. Ichiki,et al.  Differential inducibility of angiotensin II AT2 receptor between SHR and WKY vascular smooth muscle cells. , 1996, Kidney international. Supplement.

[5]  M. Horiuchi,et al.  Angiotensin II type 2 receptor mediates programmed cell death. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Owens,et al.  Regulation of differentiation of vascular smooth muscle cells. , 1995, Physiological reviews.

[7]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[8]  Y. Yazaki,et al.  Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. , 1994, Circulation.

[9]  A. Chiavegato,et al.  Myosin isoform expression in smooth muscle cells during physiological and pathological vascular remodeling. , 1994, Journal of vascular research.

[10]  Y. Yazaki,et al.  Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. , 1993, Circulation research.

[11]  E. E. Soltis.  Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[12]  D. Baim,et al.  Relation between activated smooth-muscle cells in coronary-artery lesions and restenosis after atherectomy. , 1993, The New England journal of medicine.

[13]  S. Kawamoto,et al.  Evidence for inserted sequences in the head region of nonmuscle myosin specific to the nervous system. Cloning of the cDNA encoding the myosin heavy chain-B isoform of vertebrate nonmuscle myosin. , 1992, The Journal of biological chemistry.

[14]  R. Rosenberg,et al.  Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. , 1992, Circulation research.

[15]  J. Sellers,et al.  Smooth muscle myosin is composed of homodimeric heavy chains. , 1992, The Journal of biological chemistry.

[16]  R. Wilensky,et al.  Vascular Smooth Muscle: A Review of the Molecular Basis of Contractility* , 1991, Circulation.

[17]  M. Daemen,et al.  Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. , 1991, Circulation research.

[18]  H. Baumgartner,et al.  Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.

[19]  S. Kawamoto,et al.  Characterization of myosin heavy chains in cultured aorta smooth muscle cells. A comparative study. , 1987, The Journal of biological chemistry.

[20]  G. Owens.  Differential effects of antihypertensive drug therapy on vascular smooth muscle cell hypertrophy, hyperploidy, and hyperplasia in the spontaneously hypertensive rat. , 1985, Circulation research.

[21]  T. Ichiki,et al.  Angiotensin II Receptors AT1 and AT2 , 1997 .

[22]  K. Katayama,et al.  Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting-enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. , 1996, Journal of cardiovascular pharmacology.

[23]  M. Safar,et al.  Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. , 1994, Hypertension.

[24]  Y. Notsu,et al.  The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist. , 1993, Japanese journal of pharmacology.